Senzime presents positive data from clinical study of CliniSenz

Uppsala, 12 May 2014. Senzime AB (publ) today announced that results from a clinical study of the company's instrument for automatic and continuous monitoring of blood sugar levels - CliniSenz^TM - confirm the possibility to identify fluctuations that could not be detected by existing methods. This situation may contribute to increased survival during complicated surgical procedures.The study was conducted at the Uppsala University Hospital and covers some 40 individuals (volunteers and patients). The results indicate high precision and longer measurement periods with CliniSenz^TM than with the test methods that are currently used in the hospital.

The study was conducted at the Uppsala University Hospital and covers some 40 individuals (volunteers and patients). The results indicate high precision and longer measurement periods with CliniSenz^TM than with the test methods that are currently used in the hospital. 

"Earlier identification of blood glucose level fluctuations is important in intensive care and may also be important in other health care disciplines", says Per-Olof Joachimsson, medical management responsible for Thoracic Surgery and anesthesia, Uppsala University Hospital.

Examples of other potential applications outside the hospital environment include the monitoring of blood glucose levels to demonstrate the effect of food intake and physical exercise for managing diabetes and overweight. 

"The clinical study of CliniSenz^TM confirms that the instrument is reliable and user-friendly. The need to continuously monitor blood sugar levels is high, both in health care settings and to increase the awareness of, for example, individuals with diabetes and overweight on how physical activity and food intake can affect their health. Senzime is now looking for a corporate partner to further develop CliniSenz^TM and we will also continue the development in-house for niche applications", said Lena Söderström, CEO of Senzime AB.

Lena Söderström, CEO of Senzime AB

Tel: +46-708-16 39 12, e-mail: lena.soderstrom@senzime.com

Senzime develops and sells analytical instruments and related disposable products that enable automated, continuous monitoring of vital substances including glucose (sugar), in biological fluids. Many modern medicines are produced in living cells that are nourished in a glucose solution. In order to ensure maximum productivity in manufacturing, glucose levels should be measured continuously. BioSenz^TM is an analytical instrument that performs this task. Senzime's market leading partner, Applikon, has started the global launch of BioSenz^TM. Continuous glucose monitoring can also be used by healthcare providers, to improve outcomes of complex surgical procedures and dialysis care. For these purposes, the company develops the instrument CliniSenz^TM. The company's share is listed on Aktietorget since 2008.

www.senzime.com